You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

triple-hit DLBCL

Showing 1 - 25 of 2,765
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Lymphoma, Relapsed Lymphoma, Refractory Lymphoma Trial in United States (fimepinostat, Rituximab, venetoclax)

Completed
  • Lymphoma
  • +10 more
  • Los Angeles, California
  • +10 more
May 5, 2021

Double Hit Lymphoma, Triple Hit Lymphoma Trial in Hangzhou (Selinexor+RCHOP)

Recruiting
  • Double Hit Lymphoma
  • Triple Hit Lymphoma
  • Hangzhou, Zhenjiang, China
    Zhejiang Cancer Hospital
Aug 2, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 12, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Predict CNS Involvement in Diffuse Large B-Cell Lymphoma:Danish

Completed
  • Diffuse Large B Cell Lymphoma
  • +2 more
    • (no location specified)
    Dec 13, 2021

    Diffuse Large B-cell Lymphoma Trial in Worldwide (Epcoritamab, Investigator's Choice Chemotherapy)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Epcoritamab
    • Investigator's Choice Chemotherapy
    • Irvine, California
    • +254 more
    Jan 9, 2023

    Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Jan 20, 2023

    DLBCL (DLBCL) Trial (Tisagenlecleucel)

    Withdrawn
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • Tisagenlecleucel
    • (no location specified)
    Feb 25, 2022

    Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer Trial in United Kingdom (NX-1607)

    Recruiting
    • Ovarian Cancer, Epithelial
    • +14 more
    • Sutton, Surrey, United Kingdom
    • +6 more
    Jul 22, 2022

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

    Recruiting
    • Non Hodgkin Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Nanjing, Jiangsu, China
    • +1 more
    Mar 9, 2022

    DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +2 more
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 5, 2023

    Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

    Recruiting
    • Malignancy
    • +14 more
    • Scottsdale, Arizona
    • +17 more
    Mar 7, 2022

    B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma (B-NHL)
    • B-cell Acute Lymphoblastic Lymphoma (B-ALL)
    • PIT565
    • (no location specified)
    Jun 13, 2022

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Orelabrutinib + R-CHOP
    • Placebo + R-CHOP
    • Shanghai, Shanghai, China
      Shanghai Ruijing Hospital
    Nov 28, 2022

    Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

    Active, not recruiting
    • Adult Diffuse Large Cell Lymphoma
    • +2 more
    • DPX-Survivac
    • +2 more
    • Calgary, Alberta, Canada
    • +5 more
    Nov 9, 2022

    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +4 more
    • Tampa, Florida
      Moffitt Cancer Center
    Jan 12, 2023

    Aesthetic Trial in Montreal (Restylane line of injectable)

    Recruiting
    • Aesthetic
    • Restylane line of injectable
    • Montreal, Quebec, Canada
      Erevna Innovations Inc
    Apr 6, 2023

    Heparin-induced Thrombocytopenia, HIT, Platelet Activation Trial in Amiens (blood sample)

    Recruiting
    • Heparin-induced Thrombocytopenia
    • +7 more
    • blood sample
    • Amiens, France
      CHU Amiens
    Sep 12, 2023

    DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

    Approved for marketing
    • DLBCL
    • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
    • (no location specified)
    Aug 26, 2020

    Heparin-induced Thrombocytopenia in Post-operative Cardiac

    Recruiting
    • Heparin-induced Thrombocytopenia
    • Post screening diagnostic test
    • Vandœuvre-lès-Nancy, Meurthe Et Moselle, France
      'CHRU Nancy
    Mar 23, 2023

    DLBCL Trial in China, United States (Enzastaurin Hydrochloride, R-CHOP + )

    Completed
    • Diffuse Large B-Cell Lymphoma
    • Enzastaurin Hydrochloride
    • R-CHOP + placebo
    • Huntsville, Alabama
    • +38 more
    Jul 28, 2022